BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive tests to monitor immune status in transplant recipients and autoimmune diseases, today announced the launch of AlloMap® Molecular Expression Testing in Germany. AlloMap is XDx’s easy and convenient, non-invasive blood test that aids physicians in determining a stable heart transplant patient’s risk of acute cellular rejection without requiring the use of endomyocardial biopsy. Heart transplant specialists initiated use of AlloMap in selected German hospitals in March 2012, and XDx expects to make AlloMap available to additional German, Swiss and Austrian transplant centers throughout the second quarter of this year in the first stage of a broader European launch.
